Home » Diffuse large B-cell lymphoma, a new treatment available for patients already undergoing two or more lines of therapy

Diffuse large B-cell lymphoma, a new treatment available for patients already undergoing two or more lines of therapy

by admin
Diffuse large B-cell lymphoma, a new treatment available for patients already undergoing two or more lines of therapy

by Health Editorial Staff

A defined-duration treatment with a bispecific antibody has been approved in Italy and has been shown to determine complete and long-lasting responses

Diffuse large B-cell lymphoma, the most common form of non-Hodgkin’s lymphoma, accounts for approximately 30% of all aggressive lymphomas, which have a more rapid clinical course and require timely treatment. It is a blood cancer characterized by rapid growth of B lymphocytes, a type of white blood cell (immune system cells), which is diagnosed in approximately 13,200 Italians every year. Although a considerable percentage of patients respond positively to initial treatment, nearly four in ten show no response or experience a relapse. Precisely for relapsed or refractory patients, after two or more lines of systemic therapy, the Italian Medicines Agency (Aifa) has recently granted reimbursement to a new medicine, glofitamab.

Bispecific antibodies

«Patients with this hematological neoplasm, heavily pre-treated or refractory, unfortunately had few therapeutic alternatives – clarifies Paolo Corradini, full professor of Hematology at the University of Milan -. In recent years the therapeutic panorama has been enriched with new innovative and effective therapies and the approval of glofitamab represents one of these innovations. The data confirm the important role of CD20xCD3 bispecific antibodies in the treatment of non-Hodgkin B lymphomas, both aggressive and indolent, showing how a defined duration therapy can determine complete and long-lasting responses even after the end of treatment. From this perspective, the rationale of ongoing clinical studies is also confirmed, in which bispecific antibodies are tested in combination strategies in the early treatment lines of diffuse large B-cell lymphoma and follicular lymphoma.” Bispecific antibodies are called this because they are composed of two parts: one recognizes the target on the surface of the tumor cell and the other binds to a healthy T cell of our immune system, bringing it close to the tumor cell, so the T cell becomes activated and destroys it.

A new type of immunotherapy

Glofitamab is a new type of immunotherapy: its mechanism of action makes it particularly effective and capable of inducing complete, fast and long-lasting responses in patients with lymphomas that are heavily pre-treated or refractory to previous therapies, including CAR-T. Furthermore, its administration for a fixed period of time (12 cycles of 21 days, equal to approximately 8 months) allows patients to know when the treatment will end. «Aifa’s approval of glofitamab represents a significant milestone in the fight against diffuse large B-cell lymphoma, which presents considerable therapeutic challenges, with a significant number of patients who do not benefit from current standards of care – says Carmelo Carlo -Stella, full professor of Hematology at Humanitas University and head of the Lymphoid Neoplasms section at the IRCCS Humanitas Clinical Institute of Milan -. Data from clinical trials demonstrate that glofitamab can maintain remissions in many heavily pretreated patients, offering new hope. Thanks to its targeted design, which involves CD20 on malignant B cells and CD3 on T cells, the molecule activates a specific immune response against tumor cells.”

See also  Expert Advice: What to Avoid Eating at a Breakfast Buffet for a Healthy Start to your Day

Patient associations

The approval by Aifa is based on the results of the pivotal study (phase I/II NP30179) which, with an updated median follow-up of 32 months, demonstrated how glofitamab is able to maintain complete responses lasting over time, administered for up to 12 cycles (approximately eight months), in patients with relapsed or refractory diffuse large B-cell lymphoma who have received at least two previous lines of therapy. In fact, after such a long-term median follow-up, 55% of patients with a complete response (CR) were still in remission at 24 months. The majority of these patients remained progression-free and were still alive 18 months after completing fixed-duration treatment with glofitamab. Efficacy is maintained even in the most compromised patients who had previously received CAR-Ts. Glofitamab is also well tolerated. The most common adverse event was cytokine release syndrome, but limited to the first cycle and manageable. Discontinuations due to adverse events were rare and occurred in only 2.8% of patients.

Save precious time

«In oncology hematology, research is accustoming us to continuous innovation that is slowly changing the history of various diseases, even in advanced stages or in situations with few therapeutic prospects – comments Davide Petruzzelli, president of the Aladdin’s Lamp association -. The approval of glofitamab offers patients an important opportunity and introduces elements that can significantly impact the quality of life, such as the fixed duration of therapy which allows them to gain precious time to dedicate to themselves again, but also its distribution widespread throughout the territory which facilitates access”. «As a patient association committed for over 50 years to providing support and information to those fighting against onco-haematological pathologies, the approval of this innovative therapy makes us happy and confident because it allows us to facilitate treatment and gives patients the opportunity to earn precious time avoiding prolonged hospitalization” concludes Giuseppe Gioffrè, AIL lymphoma patient group representative.

See also  "Vascular study" successfully started - medicine and health, medical specialists and wellness

Do you have a doubt or medical question?

Our doctors and specialists answer your questions on health topics

April 22, 2024 (modified April 22, 2024 | 1:06 pm)

© ALL RIGHTS RESERVED

Do you have a doubt or medical question?

Our doctors and specialists answer your questions on health topics

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy